Cat. No.: HY-149393

RIPK3-IN-3

Customer Review

Based on 1 Customer Validation

RIPK3-IN-3 (compound 20) is a selective inhibitor of RIP kinase RIPK3 (IC₅₀=10 nM). RIPK3 mediates the phosphorylation of Mixed Lineage Kinase (MLKL) and causes necroptosis, while RIPK3-IN-3 inhibits p-MLKL oligomerization and thereby inhibits necroptosis. RIPK3-IN-3 also downregulates CXCL5 secretion and inhibits AsPC-1 cell migration and invasion.

For research use only. We do not sell to patients.

Purity: 95.98%
CAS No.: 3052303-53-1
Formula: C₁₆H₁₁N₅S
Molecular Weight:305.36

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

RIPK3-IN-3 Chemical Structure

CAS No.: 3052303-53-1

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

IC50: 10 nM (RIPK3)^[1]

All RIP kinase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HT-29	CC₅₀	>50 μM Compound: 20	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by celltiter glo assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by celltiter glo assay	[PMID: 37494773]

In Vitro

Western Blot Analysis ^[1]

Cell Line:

HT-29 cell
Concentration:

10, 25, 50 μM
Incubation Time:

2 h
Result:

Inhibited phosphorylation of RIPK3 and MLKL in a concentration dependent manner.

Cell Viability Assay ^[1]

Cell Line:

U937 cells, HT-29cell
Concentration:

20,50 μM
Incubation Time:

2 h
Result:

Decreased PI-positive cells to Hoechst-positive cells ratio.
Rescued the cell from the TCZ-induced cell necroptosis.

Cell Migration Assay ^[1]

Cell Line:

AsPC-1 cell
Concentration:

20,50 μM
Incubation Time:

24 h
Result:

Suppressed migration capability of AsPC-1 pancreatic cancer cells in a dose dependent manner.

Cell Invasion Assay^[1]

Cell Line:

AsPC-1 cell
Concentration:

20,50 μM
Incubation Time:

2 h
Result:

Suppressed invasion capability of AsPC-1 pancreatic cancer cells in a dose dependent manner.

In Vivo

Animal Model:

TNF-induced SIRS model (C57BL/6 female mice)^[1]
Dosage:

10 or 25 mg/kg, single dose, TNFα (7 μg/mouse, iv)
Administration:

Intraperitoneal injection (i.p.)
Result:

Protects mice against lethal shock which is induced by TNFα and relieved the TNFα-induced temperature loss in a dose-dependent manner.
Decreases TNFα-induced IL-6 production in the mouse serum.

Chemical Information

CAS No. 3052303-53-1
Appearance Solid
Molecular Weight 305.36
Formula C₁₆H₁₁N₅S
Color Light yellow to yellow
SMILES

C=CC1=NC=C2N=CN=C(NC3=CC(N=CS4)=C4C=C3)C2=C1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (327.48 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2748 mL

16.3741 mL

32.7482 mL

5 mM

0.6550 mL

3.2748 mL

6.5496 mL

10 mM

0.3275 mL

1.6374 mL

3.2748 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.19 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Namkyoung Kim, et al. Identification of Pyrido[3,4-d]pyrimidine derivatives as RIPK3-Mediated necroptosis inhibitors. Eur J Med Chem. 2023, 259, 115635. [Content Brief]

[2]. Kim N, et al. Identification of Pyrido [3, 4-d] pyrimidine derivatives as RIPK3-Mediated necroptosis inhibitors[J]. European Journal of Medicinal Chemistry, 2023, 259: 115635...

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2748 mL	16.3741 mL	32.7482 mL	81.8706 mL
	5 mM	0.6550 mL	3.2748 mL	6.5496 mL	16.3741 mL
	10 mM	0.3275 mL	1.6374 mL	3.2748 mL	8.1871 mL
	15 mM	0.2183 mL	1.0916 mL	2.1832 mL	5.4580 mL
	20 mM	0.1637 mL	0.8187 mL	1.6374 mL	4.0935 mL
	25 mM	0.1310 mL	0.6550 mL	1.3099 mL	3.2748 mL
	30 mM	0.1092 mL	0.5458 mL	1.0916 mL	2.7290 mL
	40 mM	0.0819 mL	0.4094 mL	0.8187 mL	2.0468 mL
	50 mM	0.0655 mL	0.3275 mL	0.6550 mL	1.6374 mL
	60 mM	0.0546 mL	0.2729 mL	0.5458 mL	1.3645 mL
	80 mM	0.0409 mL	0.2047 mL	0.4094 mL	1.0234 mL
	100 mM	0.0327 mL	0.1637 mL	0.3275 mL	0.8187 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

RIPK3-IN-3

Apoptosis Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Chemokine Compound Library

Cancer Stem Cells Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

All RIP kinase Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

RIPK3-IN-3 Related Classifications

Cat. No.: HY-149393